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H ealthy People 2020, an initiative released by the US De-partment of Health and Human Services, defined ournation’s current public health priorities in preven-
tion and health promotion.1,2 In the context of cancer, Healthy
People aims to increase the proportion of individuals who re-
ceive screening consistent with the US Preventive Services Task
Force (USPSTF)’s evidence-based guidelines. These guide-
lines include not only indications for cancer screening but also
cessation of screening for some conditions when there is no
evidence for net benefit or when evidence suggests screen-
ing may lead to net harm. Healthy People specifically recom-
mends using data from the National Health Interview Survey
(NHIS) to quantify progress in achieving these goals.2
There is general agreement that routine cancer screening
has little likelihood to result in a net benefit for individuals
with limited life expectancy,3,4 as reflected in the consistency
in existing guidelines. The American Society of Clinical Oncol-
ogy (ASCO), as part of their Choosing Wisely Campaign, an
initiative designed to highlight the misuse of medical tests,
recently recommended avoiding prostate-specific antigen
(PSA) screening in men who are expected to live fewer than 10
years.5 Similarly, the American Cancer Society (ACS) and the
American Urological Association (AUA) also recommend ces-
sation of PSA screening in men with a life expectancy of less
than 10 years.6,7 For colorectal cancer screening, the American
College of Physicians recommends cessation of screening in
IMPORTANCE Routine cancer screening has unproven net benefit for patients with limited life
expectancy.
OBJECTIVE To examine the patterns of prostate, breast, cervical, and colorectal cancer
screening in the United States in individuals with different life expectancies.
DESIGN, SETTING, AND PARTICIPANTS Data from the population-based National Health
Interview Survey (NHIS) from 2000 through 2010 were used and included 27 404
participants aged 65 years or older. Using a validated mortality index specific for NHIS,
participants were grouped into those with low (<25%), intermediate (25%-49%), high
(50%-74%), and very high (75%) risks of 9-year mortality.
MAIN OUTCOMES AND MEASURES Rates of prostate, breast, cervical, and colorectal cancer
screening.
RESULTS In participants with very high mortality risk, 31% to 55% received recent cancer
screening, with prostate cancer screening being most common (55%). For women who had a
hysterectomy for benign reasons, 34% to 56% had a Papanicolaou test within the past 3
years. On multivariate analysis, very high vs low mortality risk was associated with less
screening for prostate (odds ratio [OR], 0.65 [95% CI, 0.50-0.85]), breast (OR, 0.43 [95% CI,
0.35-0.53]), and cervical (OR, 0.50 [95% CI, 0.36-0.70]) cancers. There was less screening
for prostate and cervical cancers in more recent years compared with 2000, and there was
no significant interaction between calendar year and mortality risk for any cancer screening
(P> .05 for all cancers). Our sensitivity analysis showed that screening was also common in
individuals with less than 5-year life expectancy.
CONCLUSIONS AND RELEVANCE A substantial proportion of the US population with limited life
expectancy received prostate, breast, cervical, and colorectal cancer screening that is unlikely
to provide net benefit. These results suggest that overscreening is common in both men and
women, which not only increases health care expenditure but can lead to net patient harm.
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individuals with less than 10-year life expectancy.8 Other
guidelines in breast9 and cervical cancers10,11 have similarly
used life expectancy and/or age12-14 (a crude surrogate for life
expectancy) as a parameter for screening cessation. A sum-
mary of selected guidelines is presented in Table 1. The rou-
tine use of cancer screening in these individuals not only has
implications for utilization of health care resources in a set-
ting unlikely to result in net benefit but may also cause net
patient harm owing to subsequent diagnostic procedures and
overtreatment.3
The objective of this study is to examine the patterns of
routine prostate, breast, cervical, and colorectal cancer screen-
ing in the United States using data collected from the popula-
tion-based NHIS and to assess whether rates of cancer screen-
ing differ in individuals with different life expectancies. This
study allows comparison of one aspect of current practice with
the goal of Healthy People to promote evidence-based uses of
cancer screening.
Methods
Data Source and Study Cohort
The NHIS is a cross-sectional, in-person survey conducted by
the National Center for Health Statistics, and studies approxi-
mately 90 000 persons each year using a stratified, multi-
stage sampling design to provide information representative
of the US population.16 Hispanics and African Americans are
oversampled.16 Data from the NHIS have been used widely to
examine population-based patterns of health care in the United
States.17,18 Institutional review board approval for this study
was waived by the University of North Carolina.
A total of 143 592 participants were asked cancer screen-
ing questions in NHIS survey years 2000, 2003, 2005, 2008, and
2010, including 27 911 participants 65 years or older. The in-
dex used to calculate mortality risk is validated only in indi-
viduals 65 years or older. Excluding those with missing data
necessary for life expectancy calculations (507), a total of
27 404 were included in the analysis.
Outcomes
Receipt of screening tests was collected by self-report,19,20 and
time period of assessment was based on commonly recom-
mended screening frequencies, consistent with prior meth-
ods using NHIS data.21 Prior studies have described the
sensitivities of self-reported cancer screening rates for mam-
mograms, Papanicolaou tests, PSA tests, and endoscopies at
0.95, 0.93, 0.71, and 0.79, respectively; specificities are 0.61,
0.48, 0.73, and 0.90, respectively.22 Breast cancer screening was
defined as having a mammogram in the past 2 years,12 and cer-
vical cancer screening as having a Papanicolaou test in the past
3 years10—both based on USPSTF recommendations. Colorec-
tal cancer screening was defined as having any screening ex-
amination (colonoscopy, sigmoidoscopy, or fecal occult blood
test) in the past 5 years.14 The optimal frequency, if any, of pros-
tate cancer screening is controversial, and the USPSTF recom-
mends no PSA screening.15 For purposes of this study, we de-
fined prostate cancer screening as having had a PSA test in the
past 2 years, which is consistent with the screening interval
recommended by the AUA.7
To calculate the screening rates of each type of cancer,
we excluded those who had a history of the cancer in ques-
tion. In addition, to calculate the rates of cervical cancer
screening, we excluded those with a history of hysterectomy
and those with a history of cervical, uterine, or ovarian can-
cer. However, we separately calculated the rates of cervical
cancer screening (Papanicolaou tests) in women with a his-
tory of hysterectomy for benign reasons (ie, history of hys-
terectomy and no history of cancer). For cervical cancer
screening, data from 2003 could not be used because a ques-
tion about prior hysterectomy was not included in that sur-
vey year. Only women were included in the cervical and
breast cancer screening analyses, only men were included in
the prostate cancer screening analysis, and both men and
women were included in the colorectal cancer screening
analysis.
Control Variables
A validated mortality index based on NHIS data, with a C sta-
tistic of 0.75, was used to calculate 9-year mortality risk for each
participant.23 The index was designed specifically for cancer
screening applications and for participants 65 years or older,
and incorporates age, sex, smoking status, body mass index,
comorbid conditions, number of hospitalizations, perceived
health, and functional measures.23,24 We grouped partici-
pants into those with a low likelihood of mortality (<25% risk
of mortality in 9 years), intermediate likelihood (25%-49%),
high likelihood (50%-74%), and very high likelihood (≥75%).
Nine-year life expectancy was chosen for the main analysis be-
cause a validated mortality index exists, and this duration is
Table 1. Summary of Cancer Screening Cessation Criteria
in Select Guidelines
Cancer Organization Recommendation
Prostate USPSTF Recommend against PSA-based screening
for all men15
ASCO <10-y life expectancy5
ACS <10-y life expectancy6
AUA Age ≥70 y or <10-15–y life expectancy7
Breast USPSTF Age ≥75 y12
SBI, ACR <5-7–y life expectancy9
CTFPHC Age ≥75 y13
Cervical USPSTF Age >65 y,10 hysterectomy with removal of
the cervix, without history of a high-grade
precancerous lesion or cervical cancer10
ACS, ASCCP Age >65 y11
ASCP Hysterectomy11
Colorectal USPSTF Age >85 y (for ages 76-85 y, recommend
individualized decisions)14
ACP Age >75 y or <10-y life expectancy8
Abbreviations: ACP, American College of Physicians; ACR, American College of
Radiology; ACS, American Cancer Society; ASCCP, American Society for
Colposcopy and Cervical Pathology; ASCO, American Society of Clinical
Oncology; ASCP, American Society for Clinical Pathology; AUA, American
Urological Association; CTFPHC, Canadian Task Force on Preventive Health
Care; PSA, prostate-specific antigen; SBI, Society of Breast Imaging;
USPSTF, US Preventive Services Task Force.
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similar to the 10-year cutoff used by many existing guidelines
for cancer screening cessation.5-8
The NHIS collected participant-level sociodemographic
variables, including race, age, marital status, education, re-
gion, insurance status, and usual place of medical care.
Statistical Analysis
The proportions of participants who received screening for each
cancer were calculated for subgroups stratified by mortality risk,
and χ2 tests were used to assess potential differences among
groups. As a sensitivity analysis, we also calculated screening
rates based on 5-year mortality risk, using a validated 5-year
mortality index, which also has a C statistic of 0.75.24 Of note,
this 5-year mortality index does not provide risks of 75% or
higher; therefore, a very high risk group was not created for
analysis. Logistic regression models were used to assess po-
tential factors associated with screening, and a separate model
was built for each cancer. A Year × Mortality Risk interaction
term was tested in all models to assess whether trends in screen-
ing over time differed by groups with different life expectan-
cies. All analyses incorporated population-based sampling
weights provided by NHIS unless otherwise indicated.
Statistical analysis was conducted using SAS software (ver-
sion 9.2; SAS Institute Inc). Two-sided P values were calcu-
lated, with P< .05 considered statistically significant.
Results
Table 2 describes the weighted characteristics of the 27 404 par-
ticipants included in this study, stratified by mortality risk
group. Overall, 87% were white, and 41% were married. Al-
most all (99%) had health insurance, as one would expect for
this Medicare-eligible population, and 96% identified having
a place for usual health care. There was diversity in educa-
tional levels and geographic regions in the participants.
Figure 1 and the eTable in the Supplement show the screen-
ing rates for prostate, breast, cervical, and colorectal cancers
stratified by 9-year mortality risk. The overall screening rates for
the study cohort were prostate cancer, 64% (range, 70% in in-
dividuals with low mortality risk to 55% in those with very high
mortality risk); breast cancer, 63% (range, 74% [low] to 38% [very
high]); cervical cancer, 57% (range, 70% [low] to 31% [very high]);
and colorectal cancer, 47% (51% [low] to 41% [very high]). Among
different cancers, the rate of recent screening in those with a very
high mortality risk was highest for prostate cancer (55%). In all
cancers, screening rates decreased as the risk of mortality in-
creased (P < .001 for all cancers). In sensitivity analysis, screen-
ing rates ranged from 26% to 52% for participants with high
(≥50%) 5-year mortality risk (Figure 2). Screening rates by NHIS
survey year are detailed in eFigures 1 to 4 in the Supplement.
We further examined screening rates based on age groups
because some guidelines (eg, those of the USPSTF) use age cri-
teria rather than life expectancy. The USPSTF does not recom-
mend prostate cancer screening for men of any age. For breast
cancer, screening rates were 55% (for those ≥75 years) and 72%
(for those <75 years). For cervical cancer, screening rates were
56% (for those >65 years) and 75% (for those ≤65 years). For
colorectal cancer, rates were 31% (for those ≥85 years), 46% (for
those 75-84 years), and 50% (for those <75 years).
For participants who had a hysterectomy for benign rea-
sons, Papanicolaou test was received by 56% (low mortality
risk), 45% (intermediate mortality risk), and 34% (high mor-
tality risk) of participants within the past 3 years.
Table 3 summarizes the multivariate models examining fac-
tors associated with cancer screening. Increasing risk of mor-
tality was associated with decreased odds of screening for all
but colorectal cancer. In addition, older age was indepen-
dently associated with less screening for all cancers. For pros-
tate cancer, age older than 84 years was associated with de-
creased screening compared with those ages 65 to 69 years (odds
ratio [OR], 0.69 [95% CI, 0.50-0.94]). For breast (age 75 years),
cervical (age 70 years), and colorectal (age 80 years) cancers,
decreased rates of screening seemed to start at younger ages.
Participants who were married, had more education, had in-
surance coverage, or had a usual place of care were more likely
to receive screening. Screening decreased for prostate and cer-
vical cancers in more recent years compared with 2000. A
Year × Mortality Risk interaction term was tested and was found
to be nonsignificant in all 4 models (P = .34 for prostate can-
cer; P = .58, breast cancer; P = .63, cervical cancer; P = .52, co-
lorectal cancer), so it was not retained in the final models.
Discussion
In this study, we used recent results from the population-
based NHIS to examine the rates of prostate, breast, cervical,
and colorectal cancer screening in groups of individuals with
different levels of 9-year and 5-year life expectancies based on
validated NHIS-specific mortality indices. We found that groups
of individuals with higher risks of mortality (ie, lower life ex-
pectancy) had lower rates of prostate, breast, and cervical can-
cer screening. Still, a sizable proportion of the US population
who have a less than a 9-year life expectancy (≥75% mortality
risk) received cancer screening, including 55% in the group who
received prostate cancer screening. When examined by age cri-
teria, which are used by certain guidelines, such as those of
the USPSTF, a similar finding emerged of a large proportion of
individuals receiving cancer screening who are not recom-
mended by guidelines. While prostate and cervical cancer
screening rates decreased in more recent years compared with
2000, this trend did not have a differential impact on indi-
viduals in different life expectancy groups.
To our knowledge, this is the first study to examine the
population-based screening patterns for all 4 cancers by life
expectancy. While overscreening in prostate cancer has been
widely reported,25,26 whether overscreening occurs on a popu-
lation-level in other cancers has not been well studied. Fur-
thermore, our use of life expectancy is important, and there
is increasing recognition in the literature and published guide-
lines that age alone is insufficient to determine appropriate-
ness of screening. A recent report by Bellizzi et al27 used NHIS
data to examine rates of prostate, breast, cervical, and colo-
rectal cancer screening in 2005 and 2008 among individuals
75 years or older but recognized that screening in older indi-
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viduals who are healthy may indeed be appropriate.27,28 Like
the study by Bellizzi et al,27 prior studies examining screen-
ing rates in the United States were limited by a lack of comor-
bidity and health status data, which are important in clinical
decision-making and necessary for calculation of individual
life expectancy. Age alone is insufficient to assess whether an
individual is likely to have net benefit from screening or to
evaluate whether overscreening occurs on a population
level.26-28 Emphasizing this, the American College of Physi-
cians recently recommended basing decisions to screen for
prostate cancer in part on the patient’s general health and life
expectancy, as does the 2013 ASCO Choosing Wisely
recommendations.5,29 This study is timely based on these re-
cent recommendations and also provides data on screening
trends over the past 10 years. While our results demonstrate
that physicians and patients do take life expectancy into con-
sideration, they raise concerns about overscreening in indi-
viduals who are unlikely to have net benefit from it.
In published guidelines, 10-year life expectancy is com-
monly used for clinical decision-making regarding cancer
Table 2. Characteristics of the 27 404 National Health Interview Survey Participants Included in This Studya















(n = 27 404)
Age, y
65-69 4297 (52) 2246 (25) 845 (13) 229 (5) 7617 (27)
70-74 2747 (33) 2447 (27) 1005 (15) 343 (7) 6542 (23)
75-79 1013 (12) 2379 (28) 1541 (24) 731 (17) 5664 (21)
80-84 206 (3) 1254 (15) 1685 (27) 1119 (26) 4264 (16)
≥84 0 329 (4) 1187 (20) 1801 (45) 3317 (13)
Marital status
Married 3902 (49) 3788 (44) 2166 (35) 1350 (32) 11 206 (41)
Unmarried 4325 (52) 4848 (56) 4084 (65) 2866 (68) 16 123 (58)
Missing data 36 (<1) 19 (<1) 13 (<1) 7 (<1) 75 (<1)
Education
<High school graduate 3012 (30) 3652 (36) 3011 (43) 2275 (48) 11 950 (38)
High school graduate 1477 (21) 1575 (22) 1144 (22) 689 (19) 4885 (21)
Some college 1959 (25) 1828 (22) 1206 (20) 668 (18) 5661 (22)
College graduate 1725 (24) 1526 (19) 826 (14) 506 (13) 4583 (18)
Missing data 90 (<1) 74 (<1) 76 (1) 85 (2) 325 (<1)
Health insurance
Yes 8134 (99) 8570 (99) 6220 (99) 4193 (99) 27 117 (99)
No or unknown 129 (1) 85 (1) 43 (1) 30 (1) 287 (1)
Have a place for health care
Yes 7834 (96) 8294 (96) 6057 (97) 4122 (97) 26 307 (96)
No usual place of care 392 (4) 338 (4) 193 (3) 90 (2) 1013 (4)
Missing data 37 (<1) 23 (<1) 13 (<1) 11 (<1) 84 (<1)
NHIS year
2000 1913 (16) 1955 (16) 1333 (15) 877 (14) 6078 (16)
2003 1705 (17) 1801 (17) 1253 (16) 869 (16) 5628 (17)
2005 1736 (16) 1901 (17) 1387 (17) 939 (17) 5963 (16)
2008 1299 (25) 1337 (25) 1032 (26) 684 (26) 4352 (25)
2010 1610 (26) 1661 (26) 1258 (27) 854 (27) 5383 (26)
Race
White 6953 (88) 7204 (87) 5201 (88) 3468 (87) 22 826 (87)
Nonwhite 1310 (12) 1451 (13) 1062 (12) 755 (13) 4578 (13)
Sex
Male 1891 (23) 3726 (42) 2698 (43) 2204 (51) 10 519 (38)
Female 6372 (77) 4929 (58) 3565 (57) 2019 (49) 16 885 (62)
Region
Northeast 1657 (21) 1742 (21) 1188 (20) 772 (19) 5359 (21)
Midwest 1897 (25) 1971 (24) 1478 (24) 1007 (25) 6353 (24)
South 2931 (34) 3159 (36) 2356 (37) 1614 (38) 10 060 (36)
West 1778 (20) 1783 (29) 1241 (19) 830 (18) 5632 (19)
Abbreviation: NHIS, National Health
Interview Survey.
a Numbers shown are crude numbers.
Percentages were calculated using
population-based sampling weights
provided by the NHIS.
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screening5-8 because survival benefits from screening within
10 years are unproven or small. In this study, the 31% to 55%
rates of routine cancer screening in individuals with less than
a 9-year life expectancy (≥75% risk of mortality in 9 years) dem-
onstrate that guideline-discordant use of cancer screening is
common. Rates of overscreening for prostate cancer are espe-
cially high, possibly because PSA testing is viewed as a simple,
safe blood test, with little recognition of the important down-
stream harms. Overscreening occurs even in individuals with
less than a 5-year life expectancy. These results from the sen-
sitivity analysis further demonstrate the magnitude of over-
screening across the United States. It is widely accepted that
individuals with less than a 5-year life expectancy will not have
net benefit from cancer screening.3,27,28
Another guideline-discordant screening we examined was
Papanicolaou tests for women who had a hysterectomy for be-
nign reasons.10 This was received by 34% to 56% of these
women, and the finding is consistent with that of a prior
report30 of rates from 1992 to 2002. However, for a small pro-
portion of these women who may have had a hysterectomy but
retained their cervix, Papanicolaou tests may be appropriate.
We also found that individuals who were married, had
more education, had insurance coverage, or had a usual place
of care were more likely to receive screening across all 4 can-
cers. It is not surprising that individuals with insurance and a
usual place of care had more access to cancer screening tests,
but our findings suggest that overscreening may be more com-
mon in married and more highly educated individuals. The
cause of this is unknown but suggests an opportunity for in-
creased educational efforts regarding the potential net ben-
efits and harms of cancer screening, especially in individuals
with limited life expectancy.
Our results highlight the challenges to implementing evi-
dence-based screening guidelines on a population level. While
the lack of net benefit from cancer screening in individuals with
limited life expectancy is widely recognized and publicized in
clinical practice guidelines, important obstacles exist to reli-
ably applying these guidelines clinically. One such obstacle is
the lack of a readily available and easy-to-use clinical tool to
accurately assess life expectancy for each patient31,32; the mor-
tality index used in this study may be too cumbersome for clini-
cal use. Without simple and reliable ways to assess 10-year life
expectancy in the clinic, guidelines may be impractical for clini-
cal adherence, which may partially explain the findings of this
study. Furthermore, even when limited life expectancy is rec-
ognized, the physician may have difficulty communicating this
prognosis and/or the patient may have difficulty accepting a
limited life expectancy or cessation of screening. The prac-
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breast cancer screening, n = 11 251;
cervical cancer screening, n = 5024;
colorectal cancer screening,
n = 17 900.
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tice of defensive medicine and fear of litigation33-35 may fur-
ther contribute to overscreening. A prior study36 that demon-
strated routine screenings in patients with advanced cancer
showed a similar pattern (though of a smaller magnitude) in
another group of individuals in whom omission of screening
should be relatively uncontroversial. Together, these studies
demonstrate a clear need for research to assess ways that can
effectively reduce overscreening.
Table 3. Multivariate Logistic Regression Models for Recent Cancer Screening
Covariate
Type of Cancer
Prostatea Breastb Cervicalc Colorectald
OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value OR (95% CI) P Value
9-y Risk of mortality
Low 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Intermediate 0.88 (0.72-1.06) .18 0.77 (0.68-0.88) <.001 0.82 (0.69-0.98) .03 0.97 (0.88-1.06) .51
High 0.72 (0.57-0.92) .007 0.63 (0.54-0.74) <.001 0.73 (0.58-0.92) .008 0.93 (0.83-1.05) .22
Very high 0.65 (0.50-0.85) .001 0.43 (0.35-0.53) <.001 0.50 (0.36-0.70) <.001 1.07 (0.92-1.26) .37
Age, y
65-69 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
70-74 1.11 (0.94-1.31) .22 0.94 (0.82-1.08) .40 0.68 (0.55-0.84) <.001 1.09 (0.99-1.20) .08
75-79 1.47 (1.20-1.79) <.001 0.83 (0.72-0.96) .01 0.52 (0.42-0.64) <.001 1.07 (0.96-1.19) .24
80-84 1.00 (0.79-1.26) .98 0.73 (0.62-0.86) <.001 0.38 (0.30-0.49) <.001 0.80 (0.70-0.92) .002
≥84 0.69 (0.50-0.94) .02 0.38 (0.31-0.46) <.001 0.23 (0.17-0.31) <.001 0.47 (0.40-0.56) <.001
Marital status
Married 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Unmarried 0.79 (0.69-0.90) <.001 0.72 (0.65-0.81) <.001 0.74 (0.62-0.87) <.001 0.77 (0.72-0.84) <.001
Education
Less than high school graduate 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
High school graduate 1.49 (1.22-1.81) <.001 1.40 (1.19-1.64) <.001 1.28 (1.06-1.54) .01 1.27 (1.12-1.43) <.001
Some college 1.80 (1.48-2.19) <.001 1.58 (1.38-1.80) <.001 1.70 (1.41-2.04) <.001 1.65 (1.50-1.82) <.001
College graduate 2.28 (1.92-2.71) <.001 2.16 (1.81-2.57) <.001 2.06 (1.60-2.66) <.001 2.00 (1.79-2.23) <.001
Health insurance
Yes 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
No or unknown 0.44 (0.25-0.76) .003 0.43 (0.24-0.78) .005 0.40 (0.19-0.84) .02 0.51 (0.33-0.79) .003
Have a place for health care
Usual place 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
No usual place 0.19 (0.13-0.26) <.001 0.16 (0.12-0.21) <.001 0.21 (0.15-0.30) <.001 0.21 (0.16-0.28) <.001
NHIS survey year
2000 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
2003 1.04 (0.85-1.27) .72 1.03 (0.90-1.18) .64 NAe NAe 2.15 (1.94-2.38) <.001
2005 0.45 (0.38-0.54) <.001 0.77 (0.68-0.88) <.001 0.61 (0.51-0.73) <.001 1.31 (1.18-1.46) <.001
2008 0.56 (0.47-0.69) <.001 0.82 (0.72-0.95) .006 0.56 (0.46-0.67) <.001 2.33 (2.07-2.63) <.001
2010 0.46 (0.35-0.61) <.001 0.96 (0.78-1.18) .67 0.52 (0.40-0.67) <.001 1.90 (1.65-2.19) <.001
Race
White 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Nonwhite 0.83 (0.70-0.99) .03 1.00 (0.87-1.13) .94 1.06 (0.88-1.27) .55 0.84 (0.76-0.92) <.001
Sex
Male NA NA NA NA NA NA 1 [Reference] NA
Female NA NA NA NA NA NA 0.93 (0.85-1.01) .10
Region
Northeast 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA 1 [Reference] NA
Midwest 1.11 (0.91-1.35) .30 1.08 (0.94-1.24) .30 1.07 (0.88-1.31) .48 0.97 (0.87-1.09) .60
South 1.06 (0.89-1.28) .50 1.04 (0.91-1.20) .55 1.26 (1.04-1.52) .02 0.89 (0.80-0.99) .03
West 0.76 (0.63-0.92) .005 1.13 (0.97-1.32) .10 1.08 (0.88-1.33) .47 0.99 (0.88-1.12) .89
Abbreviations: NA, not applicable; NHIS, National Health Interview Survey;
OR, odds ratio.
a Screening defined as a prostate-specific antigen test in the past 2 years.
b Screening defined as a mammogram in the past 2 years.
c Screening defined as a Papanicolaou test in the past 3 years.
d Screening defined as any colorectal screening examination (sigmoidoscopy,
colonoscopy, or fecal occult blood test) in the past 5 years.
e 2003 Papanicolaou test data excluded because there was no question about
prior hysterectomy in this survey year.
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This study has implications regarding the critical issue of
skyrocketing health care costs. Eliminating “waste,” or not
value-added care, in US health care has been identified as
an appropriate way to bring health care expenditure to a
sustainable level.37 Excessive cancer screening in individu-
als with limited life expectancy has been previously identi-
fied as an area of wasteful care.36 Specifically, the costs of
overdetection and overtreatment in prostate cancer have
been reported. While the screening test itself (PSA) is not
costly, using this test in men who have a limited life expec-
tancy leads to downstream consequences of cancer (over)
diagnoses and (over)treatments that are costly and unlikely
to provide net benefit to the patient.38-41 Similar concerns
regarding the cost-effectiveness of breast cancer screening
in the older populations exist, and the economic benefits of
using age with health status as a screening threshold have
been advocated.42 Our study finds overscreening in some of
the most common cancers and identifies a significant
opportunity: by reducing or eliminating the currently fre-
quent use of cancer screening in individuals with limited
life expectancy, we can decrease waste in health care spend-
ing and simultaneously improve patient outcomes on a
population level by minimizing the unnecessary harms
from cancer screening.43,44
A limitation of this study is that NHIS data are by partici-
pant self-report; the screening rates and other information col-
lected are not confirmed with medical records. A prior study22
showed that self-reports may underestimate PSA screening
rates, although other studies found an overestimation of mam-
mogram and Papanicolaou test screening rates.22 Despite this
limitation, the NHIS has a high annual response rate of close
to 90%,16 and its data are commonly used to examine popu-
lation-based health care patterns across the United States. It
is also the data set that Healthy People 2020 recommends for
monitoring health care patterns in this country. Further-
more, although different guidelines have recommended dif-
ferent life expectancies or age cutoffs for cessation of cancer
screening, our examination of screening rates in the group of
individuals with less than a 9-year life expectancy likely rep-
resents a conservative estimate of the rates of overscreening
on a population level. Our finding of frequent uses of cancer
screening in individuals with less than a 5-year life expec-
tancy further demonstrates the magnitude of this issue.
Conclusions
A substantial proportion of the US population with limited life
expectancy received prostate, breast, cervical, and colorectal
cancer screening that is unlikely to provide net benefit. These
results raise concerns about overscreening in these individu-
als, which not only increases health care expenditure but can
lead to patient net harm. Creating simple and reliable ways to
assess life expectancy in the clinic may allow reduction of un-
necessary cancer screening, which can benefit the patient and
substantially reduce health care costs. There is a consider-
able need for further dissemination efforts to educate physi-
cians and patients regarding the existing screening guide-
lines and potential net harm from screening in individuals with
limited life expectancy.
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Invited Commentary
Cancer Screening in Older Persons
A New Age of Wonder
Cary P. Gross, MD
The process of scientific discovery is, in effect, a continual flight from
wonder.
Albert Einstein
The second half of the 20th century was truly an age of won-
der for cancer screening. In 1943, when Papanicolaou and
Traut1 first published reports of a new method for cervical can-
cer screening, cervical can-
cer was still a major cause of
death. By the 1950s, cervical
cancer screening was being
performed at hundreds of centers across the country; over the
following 40 years, cervical cancer incidence and mortality de-
creased by 60%.2 Screening for other types of cancer was in-
troduced soon afterward (mammography in 1963, colonos-
copy in 1969)—and the use of screening increased greatly.
Although cures for many cancers remained frustratingly elu-
sive, screening was attractive because it seemed reassuringly
actionable: people could do their part, by either undergoing
screening tests themselves or encouraging others to do so.
Cancer screening in the 21st century, however, is losing its
luster. Increasing evidence suggests that many modalities of
cancer screening may be far less beneficial than first thought.
Screenings that used to be straightforwardly recommended,
such as the prostate-specific antigen test, are now discour-
aged by many experts. Emerging mammography data show
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